Traduction de «make available both this information » (Néerlandais → Français) :

The Council urges the authorities competent for public health to make available both this information and these warnings to the target audience of energy drinks. Finally, it requests the legislator to take the necessary measures concerning the labelling of these drinks, especially as far as the recommendations mentioned in this report are concerned.
Enfin, il encourage les autorités de Santé à diffuser, auprès du public cible des boissons énergisantes, les informations reprises ci-avant ainsi que les mises en garde énoncées et sollicite le législateur pour qu’il prenne des dispositions utiles concernant l’étiquetage de ces boissons, notamment quant aux recommandations évoquées dans ce rapport.

The Council urges the authorities competent for public health to make available both this information and these warnings to the target audience of energy drinks. Finally, it requests the legislator to take the necessary measures concerning the labelling of these drinks, taking especially into account the recommendations mentioned in this report.
Enfin, il encourage les autorités de Santé à diffuser, auprès du public cible des boissons énergisantes, les informations reprises ci avant ainsi que les mises en garde énoncées et sollicite le Législateur pour qu’il prenne des dispositions utiles concernant l’étiquetage de ces boissons, notamment quant aux recommandations évoquées dans ce rapport.

This explains why the various training programmes offered usually last for several days and those taking part are limited in number, making it is possible to address the topic both thoroughly and interactively.
C’est dans cette optique que les formations offertes sont généralement des formations de plusieurs jours pour un groupe réduit de participants: de cette façon il est possible de travailler de façon approfondie et interactive autour de la thématique.

In fact, for cases such as these, there is a whole range of methodological precautions available which make it possible to reduce this effect (guaranteed confidentiality, putting the interviewee at ease, setting, methodology used in conducting the survey…)
Il existe d’ailleurs pour ces cas-là toute une série de précautions méthodologiques qui permettent de diminuer cet effet (garantie de l’anonymat, mise en confiance de la personne interrogée, lieu de l’enquête, méthodologie de passation…).

and actions ●● Guaranty proper coordination ●● Make internal and external resources available for the different projects ●● Set up an internal change and communication plan ●● Offer an information platform for the different projects
and actions ●● Guaranty proper coordination ●● Make internal and external resources available for the different projects ●● Set up an internal change and communication plan ●● Offer an information platform for the different projects

In fact, it may be the most sensitive information there is and as new discoveries are made, and more is learned about what your genes say about you, this information is likely to become ever more sensitive over time" , centraal of perifeer: " Individuals want to have a more active role in the creation, storage and protection of their personal genetic information" , of aan de logische gevolgen van: " Not supplying genetic testing services direct-to-the-public to those under the age of 16 or to those not able to make a competent decision regarding testing" , op het huidige waarschijnlijk al meest gevraagde toepassingsgebied in de embryonale en foetale geneeskunde: " That the DTC offer of preconceptional carrier testing questions the offer of preconception care and the systematic offer of carrier tests towards a population of couples that are planning a pregnancy.
En fait, c'est peut-être même l'information la plus sensible qui soit, et si de nouvelles découvertes sont faites et que les connaissances avancent sur ce que vos gènes disent de vous, cette information deviendra probablement toujours davantage sensible au fil du temps.], centrale ou périphérique « Individuals want to have a more active role in the creation, storage and protection of their personal genetic information [traduction libre: Les gens veulent prendre une part plus active dans la genèse, la conservation et la protection de leurs données génétiques personnelles] ; les conséquences logiques de « Not supplying genetic testing services direct-to-the-public to those under the age of 16 or to those not able to make a competent decision regarding testing » [traduction libre: Ne pas fournir des tests génétiques en vente directe aux personnes âgées de moins de 16 ans ou aux personnes qui n'ont pas la capacité de prendre une décision en matière de dépistage] sur le champ d'application vraisemblablement le plus sollicité actuellement en médecine embryonnaire et fœtale : « That the DTC offer of preconceptional carrier testing questions the offer of preconception care and the systematic offer of carrier tests towards a population of couples that are planning a pregnancy.

This manual not only contains some information that makes possible a better understanding of the phenomenon, it also suggests concrete ways of action for the various parties involved and refers to the health specialists.
Ce guide ne se contente pas de fournir quelques repères pour mieux comprendre le phénomène, il offre également des pistes d’actions concrètes pour les différents intervenants, ainsi que des relais vers les spécialistes de santé.

This information is available on the FAHMP website.
This information is available on the FAHMP website.

Based on an evaluation of publicly available information about Alcon during the first half of 2009, no factors indicated that the “value in use” of this strategic investment to Novartis has fallen below the current carrying value of USD 136.84 per share (The revised carrying value from the previous level of USD 140.58 at the end of the first quarter of 2009 takes into account dividends paid in 2009 as well as other equity accounting adjustments).
Sur la base d’une évaluation des informations publiées sur Alcon au cours du premier semestre 2009, aucun facteur n’indiquait que pour Novartis, la valeur d’utilité de cet investissement stratégique était tombée en dessous de la valeur comptable d’USD 136,84 par action (cette valeur comptable inscrite au bilan et révisée par rapport à la valeur d’USD 140,58 à la fin du premier trimestre 2009, suite aux dividendes payés en 2009 ainsi que d’autres ajustements comptables résultant de l’application de la méthode de la mise en équivalence).

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.